Enzyme ImmunoAssay (EIA) is a technique to detect and quantify antigens (proteins, hormones…) or antibodies in samples. It relies on the ability of an antibody to bind a specific antigen. Either the antibody or the antigen is labelled with an enzyme whose substrate is a chromogen or a fluorogen converted in a measurable product (color or fluorescence).|Enzyme-linked Immunosorbent Assay (ELISA) is a type of EIA using a solid phase (ex: microtiter plate) coated with an antigen immobilizing the molecule to detect. Over the time, scientists have extended the term ELISA to EIAs using an antibody coating the solid phase. That explains why our EIA kits using coated antibodies are also called ELISA kits.|The QRFP-26RFa is a neuropeptide of 26 amino acids from the RFamides family (neuropeptide with an arginine and an amidated phenylalanine-motif at its C-end).|The QRFP-26RFa has been discovered in 2003 in European green frog brain. 26RFa has, since then, been characterised in many species such as human, rat and chicken. The structural analysis of the peptide exhibits an amphipathic α-helix in its central domain that plays a role in the interaction with its receptor called GPR103. The QRFP-26RFa is mainly produced in the hypothalamus and in some peripheral tissues like brainstem or the lateral horns of the spinal cord. In vivo studies in mice demonstrated that the QRFP-26RFa is an orexigenic peptide by action on the NPY/proopiomelanocortin system and by inhibition of the glucose-induced insulin secretion. QRFP-26RFa has an action on the regulation of the high fat diet and on the lipolysis in adipocyte of obese individual. In addition, some researchers study the roles of the 26Rfa in sleep and blood pressure regulation.
